6 Results

People

  1. Chansakul
    Chansakul
  2. Hassoun
    Hassoun
  3. Hultcrantz
    Hultcrantz
  4. Korde
    Korde
  5. Landgren
    Landgren
  6. Lesokhin
    Lesokhin
  7. Mailankody
    Mailankody
  8. Salcedo
    Salcedo
  9. Sams
    Sams
  10. Shah
    Shah

Groups

  1. Advanced Practice Providers (6)
  2. Bone Marrow Transplant (6)
  3. Center for Hematologic Malignancies (6)
  4. Department of Medicine (6)
  5. Hematologic Malignancies Research (6)
  6. Hematologic Malignancies, Division of (6)
  7. Myeloma (6)
  8. Nursing (6)
  9. Sloan Kettering Institute Postdocs (6)
  10. Survivorship Research (6)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Hani Hassoun"
  4. "Aisara Chansakul"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Advanced Practice Providers (6)
  2. Bone Marrow Transplant (6)
  3. Center for Hematologic Malignancies (6)
  4. Department of Medicine (6)
  5. Hematologic Malignancies Research (6)
  6. Hematologic Malignancies, Division of (6)

More Groups

People
  1. Aisara Chansakul (6)
  2. Alexander Lesokhin (6)
  3. Allison Sams (6)
  4. Carl Landgren (6)
  5. Gunjan Shah (6)
  6. Hani Hassoun (6)

More People

Years
  1. 2021 (1)
  2. 2020 (2)
  3. 2019 (2)
  4. 2018 (1)
Publications
  1. Blood (5)
  2. JAMA Oncology (1)
Publishers
  1. American Society of Hematology (5)
  2. American Medical Association (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Continuous mobile wearable bio-monitoring of newly diagnosed multiple myeloma patients undergoing initial chemotherapy
    Meeting Abstract

    Tavitian, E.; Mastey, D.; Salcedo, M.; Zarski, A.; Chansakul, A.; Diab, V.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; more...
    Blood (2018)

    Fulltext@MSK | Save